一项研究,用于调查使用或不使用Fostemsavir(FTR)使用VH3810109的研究,以减少病毒储存库的大小和活动 (ENTRANCE)
一项探索性阶段1B,多中心,随机,开放标签的研究,以研究带有或没有口服Fostemsavir静脉内VH3810109的影响,并结合基于整合酶抑制剂的抗逆转录病毒疗法对患有HIV-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Capital Region
-
Hvidovre、Capital Region、丹麦、2650
- GSK Investigational Site
-
-
Central Jutland
-
Aarhus N、Central Jutland、丹麦、8200
- GSK Investigational Site
-
-
-
-
-
Brussels、比利时、1000
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、比利时、9000
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield、California、美国、93309
- GSK Investigational Site
-
San Diego、California、美国、92103
- GSK Investigational Site
-
-
Florida
-
Ft. Pierce、Florida、美国、34982-7148
- GSK Investigational Site
-
Orlando、Florida、美国、32803-1851
- GSK Investigational Site
-
-
Illinois
-
Chicago、Illinois、美国、60611
- GSK Investigational Site
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- GSK Investigational Site
-
St Louis、Missouri、美国、63110
- GSK Investigational Site
-
-
New York
-
New York、New York、美国、10032
- GSK Investigational Site
-
-
Ohio
-
Cincinnati、Ohio、美国、45267
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- GSK Investigational Site
-
Pittsburgh、Pennsylvania、美国、15213
- GSK Investigational Site
-
-
Texas
-
Dallas、Texas、美国、75246-2004
- GSK Investigational Site
-
Dallas、Texas、美国、75208-4599
- GSK Investigational Site
-
-
-
-
-
London、英国、SE1 7EH
- GSK Investigational Site
-
London、英国、NW3 2QG
- GSK Investigational Site
-
London、英国、W2 1NY
- GSK Investigational Site
-
-
-
-
-
Rotterdam、荷兰、3015 GD
- GSK Investigational Site
-
-
-
-
-
Barcelona、西班牙、08036
- GSK Investigational Site
-
Barcelona、西班牙、08035
- GSK Investigational Site
-
Barcelona、西班牙、08003
- GSK Investigational Site
-
Barcelona、西班牙、8907
- GSK Investigational Site
-
Barcelona、西班牙、08026
- GSK Investigational Site
-
Barcelona、西班牙、08916
- GSK Investigational Site
-
Córdoba、西班牙、14004
- GSK Investigational Site
-
La Laguna Santa Cruz、西班牙、38320
- GSK Investigational Site
-
Madrid、西班牙、28041
- GSK Investigational Site
-
Madrid、西班牙、28040
- GSK Investigational Site
-
Madrid、西班牙、28046
- GSK Investigational Site
-
Madrid、西班牙、28034
- GSK Investigational Site
-
Madrid、西班牙、28031
- GSK Investigational Site
-
Madrid、西班牙、28020
- GSK Investigational Site
-
Palma de Mallorca、西班牙、07120
- GSK Investigational Site
-
Palma de Mallorca、西班牙、7198
- GSK Investigational Site
-
Seville、西班牙、41013
- GSK Investigational Site
-
Valencia、西班牙、46026
- GSK Investigational Site
-
Valencia、西班牙、46014
- GSK Investigational Site
-
-
Madrid
-
Pozuelo de Alarcón、Madrid、西班牙、28224
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
AGE
• Age between 18 years and 70 years old at the time of obtaining informed consent.
SEX AND GENDER • Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.
PARTICIPANT KEY CHARACTERISTICS • Participant has a documented diagnosis of HIV-1 infection. Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.
Population 1 only:
- Plasma HIV-1 RNA >=2000 copies/milliliter (c/mL) at Screening.
- CD4+ T cell count >=300 cells/microliter (μL) at Screening.
- Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.
Population 2 only:
- Participant is stably virologically suppressed (plasma HIV-1 RNA <50 c/mL).
- Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
- CD4+ T cell count >=450 cells/μL at Screening.
WEIGHT
• Body weight >=50 kg to <=115 kg.
INFORMED CONSENT • Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.
Exclusion Criteria:
CONCURRENT MEDICAL CONDITIONS & MEDICAL HISTORY
- Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
- Participant has documented diagnosis of HIV-2 infection.
- Participant is known to have acquired HIV via perinatal transmission.
- Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
- Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
- Ongoing or clinically relevant pancreatitis.
- Current HIV-related kidney disease.
- History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.
CARDIAC & CARDIOVASCULAR CONDITIONS
- Participants who are at clinically significant risk of cardiovascular disease.
- Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
- Confirmed QTcF value outside normal range at Screening or Day 1.
HEPATIC CONDITIONS
- History of clinically relevant hepatitis in the 6 months prior to Screening.
- Participants with severe hepatic impairment.
- Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
- Unstable liver disease.
- History of liver cirrhosis with or without hepatitis viral co-infection.
NEUROPSYCHIATRIC CONDITIONS • Participants who pose a significant suicide risk.
LABORATORY DIAGNOSTIC ASSESSMENTS
- Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
- Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
- Alanine transferase (ALT) >=3 times the upper limit of normal (ULN) at Screening.
- Estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m^2.
- Hemoglobin >=Grade 2 at Screening.
- Platelets >=Grade 2 at Screening.
- Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
- Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.
Population 2 only:
• Two or more plasma HIV-1 RNA results >=50 c/mL in the 18 months prior to Screening.
INFECTIOUS DISEASES
- Active hepatitis B virus (HBV) co-infection.
- Active hepatitis C virus (HCV) co-infection.
- Participant has untreated syphilis before enrolment.
- Known history of active Mycobacterium TB disease (regardless of treatment status).
ANTIRETROVIRAL RESISTANCE • Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.
PRIOR AND CONCOMITANT MEDICATIONS
-
Prior use of any of the following agents:
- long-acting ARVs (any dose in the past 24 months or within 5 half-lives [whichever is longer])
- FTR (any lifetime use)
- HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)
- HIV-1 monoclonal antibody therapy (any lifetime use).
-
Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.
-
History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.
-
Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.
-
Treatment with any of the following agents within 30 days of enrolment:
- radiation therapy
- cytotoxic chemotherapeutic agents
- anti-tuberculosis therapy
- immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
-
Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.
Population 1 only:
• Known use of PrEP or PEP within <30 days (for oral agents) or <52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result >=30 days after the last dose of oral PrEP or PEP (or >=52 weeks after the last dose of LA PrEP) are not excluded.
Population 2 only:
• Current use of NNRTI-containing ART.
OTHER EXCLUSIONS
- History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
- Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
- Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
- Participant is currently participating in, or anticipates being selected for, any other interventional study.
- Participant is known or suspected to be an HIV long-term non-progressor or elite controller, based on historical off-treatment plasma HIV-1 RNA results.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Participants receiving SOC INSTI-based ART in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. |
|
实验性的:Participants receiving SOC INSTI-based ART+VH3810109 in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
其他名称:
|
|
实验性的:Participants receiving SOC INSTI-based ART+VH3810109+FTR in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
其他名称:
Fostemsavir will be administered.
其他名称:
|
|
实验性的:Participants receiving VH3810109 in ATI Phase (Step 2)
|
VH3810109 will be administered.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cells
大体时间:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in total, intact, and defective proviral HIV-1 DNA per million CD4+ T cells
大体时间:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute change in cell-associated HIV-1 RNA/proviral DNA ratios in CD4+ T cells
大体时间:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute values for HIV-1-specific CD8+ T cell count
大体时间:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Change from baseline in HIV-1-specific CD8+ T cell count
大体时间:From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Number of participants with Grade 3 and Grade 4 adverse events (AEs)
大体时间:From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
Randomized Intervention Phase (Step 1): Number of participants with serious adverse events (SAEs), deaths and AEs leading to discontinuation of study intervention
大体时间:From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
ATI Phase (Step 2): Time to ART restart
大体时间:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with Grade 3 and Grade 4 AEs
大体时间:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with SAEs and deaths
大体时间:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with disease progression (HIV-associated conditions, acquired immunodeficiency syndrome [AIDS] and death)
大体时间:From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 221794
- 2025-520629-19-00 (其他标识符:EU CT Number)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.